RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+7.31%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.91B
AUM Growth
+$6.91B
(+7%)
Cap. Flow
+$117M
Cap. Flow
% of AUM
1.69%
Top 10 Holdings %
Top 10 Hldgs %
46.12%
Holding
78
New
10
Increased
15
Reduced
10
Closed
10
Top Buys
| 1 |
Geron
GERN
|
$200M |
| 2 |
Stryker
SYK
|
$143M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$16.5M |
| 4 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$16.4M |
| 5 |
Dyne Therapeutics
DYN
|
$15.5M |
Top Sells
| 1 |
Intuitive Surgical
ISRG
|
$90.1M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$71.8M |
| 3 |
Axsome Therapeutics
AXSM
|
$40M |
| 4 |
Vericel Corp
VCEL
|
$36.8M |
| 5 |
Fulcrum Therapeutics
FULC
|
$36.2M |
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Financials | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Madrigal Pharmaceuticals
MDGL
$9.76B
| $423M | 6.12% | 1,993,687 +77,825 | +4% | +$16.5M |
|
|
2
Axsome Therapeutics
AXSM
$6.05B
| $377M | 5.45% | 4,189,557 -444,774 | -10% | -$40M |
|
3
Avidity Biosciences
RNA
$5.99B
| $374M | 5.4% | 8,132,870 -673,968 | -8% | -$31M |
|
4
argenx
ARGX
$43.6B
| $355M | 5.13% | 654,430 | – | – |
|
5
Natera
NTRA
$23.1B
| $329M | 4.76% | 2,593,323 | – | – |
|
6
Rocket Pharmaceuticals
RCKT
$354M
| $327M | 4.73% | 17,687,772 | – | – |
|
7
PTC Therapeutics
PTCT
$3.92B
| $274M | 3.97% | 7,393,127 | – | – |
|
|
8
Dyne Therapeutics
DYN
$1.92B
| $245M | 3.54% | 6,818,641 +431,503 | +7% | +$15.5M |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $244M | 3.53% | 5,426,112 +139,708 | +3% | +$6.29M |
|
10
Bruker
BRKR
$5.16B
| $240M | 3.48% | 3,481,119 +37,024 | +1% | +$2.56M |
|
11
Insmed
INSM
$28.8B
| $239M | 3.46% | 3,272,008 -368,100 | -10% | -$26.9M |
|
12
Acadia Pharmaceuticals
ACAD
$4.38B
| $211M | 3.05% | 13,707,506 | – | – |
|
13
Merus
MRUS
$4.98B
| $208M | 3.01% | 4,169,393 | – | – |
|
|
14
Geron
GERN
$893M
| $200M | 2.9% | +44,111,916 | New | +$200M |
|
15
Masimo
MASI
$7.59B
| $195M | 2.82% | 1,462,400 | – | – |
|
16
Alkermes
ALKS
$4.78B
| $186M | 2.69% | 6,654,033 -402,955 | -6% | -$11.3M |
|
17
Akero Therapeutics
AKRO
$3.74B
| $170M | 2.46% | 5,919,435 +487,450 | +9% | +$14M |
|
18
Apogee Therapeutics
APGE
$2.17B
| $159M | 2.31% | 2,712,096 | – | – |
|
19
Penumbra
PEN
$10.6B
| $155M | 2.24% | 795,750 +53,645 | +7% | +$10.4M |
|
20
Immunocore
IMCR
$1.62B
| $152M | 2.19% | 4,869,798 | – | – |
|
21
Cytokinetics
CYTK
$4.23B
| $144M | 2.08% | 2,721,158 | – | – |
|
|
22
Stryker
SYK
$150B
| $143M | 2.07% | +396,921 | New | +$143M |
|
23
RadNet
RDNT
$5.52B
| $125M | 1.82% | 1,808,604 -47,406 | -3% | -$3.29M |
|
24
Establishment Labs
ESTA
$1.2B
| $114M | 1.66% | 2,645,703 -30,000 | -1% | -$1.3M |
|
25
Immatics
IMTX
$619M
| $114M | 1.65% | 10,000,000 | – | – |
|